BioNTech Results Presentation Deck
November 2021, 40 slides
  1. BioNTech
  2. Related Decks
  3. Results Presentation Decks
third quarter corporate update and financial results | BioNTech
this slide presentation includes forward looking statements | BioNTech
safety information | BioNTech
safety information | BioNTech
agenda third quarter highlights covid vaccine update oncology pipeline update financial results corporate update outlook | BioNTech
strong commercial performance and continued pipeline expansion | BioNTech
a global powerhouse a diverse pipeline of candidates next generation vaccines oncology infectious diseases and beyond potential to launch multiple products in the next years digitalization me specialized | BioNTech
harnessing the power of the immune system to address serious diseases infectious disease oncology | BioNTech
strong performance in the third quarter of third quarter highlights | BioNTech
agenda third quarter highlights covid vaccine update oncology pipeline update financial results corporate update outlook | BioNTech
a leading provider of covid vaccines globally | BioNTech
continued progress across six key levers to expand covid vaccine reach | BioNTech
clinical data support label extension of to children to years of age efficacy across age groups | BioNTech
clinical strategy supports boosters and platform approach to variants clinical trials evaluating booster dose for immunogenicity and vaccine efficacy trials evaluating variant encoding vaccines support flexible platform approach to product adaptation | BioNTech
greater neutralization and high vaccine efficacy post booster dose for protection against symptomatic disease | BioNTech
booster dose of restores high levels of vaccine effectiveness and prevents against severe disease across diverse population groups globally | BioNTech
agenda third quarter highlights covid vaccine update oncology pipeline update financial results corporate update outlook | BioNTech
potential to tackle multiple diseases with different therapeutic modalities | BioNTech
strong clinical execution on track to achieve corporate milestones randomized phase trial starts first in human phase trial starts trial updates i | BioNTech
first patient dosed in phase clinical trial in adjuvant cancer individualized specific | BioNTech
clinical data showing at provides further proof of concept of therapeutic platforms support continued advancement a a i platforms at breaker a promising signs of clinical activity and favorable safety profiles additional data to be presented at program | BioNTech
phase strong immunogenicity and promising clinical activity in cutaneous melanoma patients with evidence of disease and no evidence of disease nature | BioNTech
phase off the shelf vaccine as and in combination with inhibitor in patients with prostate cancer median age years hypertension committee i immunogenic signs of anti tumor activity no safety signals of concern | BioNTech
phase trial evaluating next generation car targeting with in solid tumors | BioNTech
phase trial favorable safety profile and encouraging signs of efficacy for car cells aes with with with symptoms clinical activity | BioNTech
phase first in human study of a next generation antibody | BioNTech
phase pharmacodynamic effects consistent with proposed mechanism of action in patients with who progressed on therapy | BioNTech
phase first in human study of a next generation antibody next generation | BioNTech
phase favorable safety profile biologic activity and early activity observed with further evaluation i tar achieved disease control | BioNTech
phase tolerable safety profile and encouraging pharmacodynamic signals with at all doses previously received i pyrexia grades non serious in of patients | BioNTech
agenda third quarter highlights covid vaccine update oncology pipeline update financial results corporate update outlook | BioNTech
and financial results unaudited profit or loss | BioNTech
and covid vaccine deliveries drove revenue growth commercial revenues identified revenue streams a | BioNTech
updated outlook for the financial year update on covid vaccine planned deliveries for the financial year planned financial year expenses and estimated financial year tax assumptions | BioNTech
agenda third quarter highlights covid vaccine update oncology pipeline update financial results corporate development outlook | BioNTech
expansion into new class of precision antibacterials with acquisition acquisition expands infectious disease | BioNTech
expanding our capabilities and pipeline in infectious diseases addressing infectious diseases with significant global impact | BioNTech
oncology pipeline product candidates in ongoing clinical trials | BioNTech
poised to accelerate our transformation i | BioNTech
a | BioNTech
See More
BioNTech
Results Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Vaccine
Cancer
Monotherapy
Manufacturing
Tumor
Clinical trial
Cell therapy
Solid tumor
Recent decks by BioNTech
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
See all presentations by BioNTech (12 decks)
Related decks
Mink Therapeutics
IPO
October 2021
Immatics
Investor Presentation
November 2023
Fusion Pharmaceuticals
IPO
June 2020
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
September 2023
Immix Biopharma
Investor Presentation
January 2024
Recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Mink Therapeutics
IPO
October 2021
Immatics
Investor Presentation
November 2023
Fusion Pharmaceuticals
IPO
June 2020
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
September 2023
Immix Biopharma
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights